(Q30390555)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20567246%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

review article

1 reference

title

PPARalpha: an emerging therapeutic target in diabetic microvascular damage (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20567246%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

0 references

Niina Hanna Talvikki Matikainen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20567246%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Marja-Riitta Taskinen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20567246%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Anne Hiukka

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20567246%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Marianna Maranghi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20567246%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

publication date

22 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20567246%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Endocrinology

6 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20567246%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20567246%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20567246%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

454-463

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20567246%20AND%20SRC:MED&resulttype=core&format=json

The pathobiology of diabetic complications: a unifying mechanism

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Effect of a multifactorial intervention on mortality in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Microvascular disease: what does the UKPDS tell us about diabetic retinopathy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Images in clinical medicine. Paget's disease of the mandible

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Familial risk factors for microvascular complications and differential male-female risk in a large cohort of American families with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Genetic factors in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Residual microvascular risk in diabetes: unmet needs and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Peroxisome proliferator-activated receptors and angiogenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Abnormal angiogenesis in diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

An update on the lipid nephrotoxicity hypothesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Inflammatory mechanisms of diabetic complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

The role of inflammatory cytokines in diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

The renin-angiotensin system and diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Nitric oxide in the kidney: functions and regulation of synthesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

NO pain: potential roles of nitric oxide in neuropathic pain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Markers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years: Association with mortality and decline of glomerular filtration rate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Saturated with fat: new perspectives on lipotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Remodeling of retinal Fatty acids in an animal model of diabetes: a decrease in long-chain polyunsaturated fatty acids is associated with a decrease in fatty acid elongases Elovl2 and Elovl4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Proliferative retinopathies: angiogenesis that blinds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Advances in the medical treatment of diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Elevated triglycerides correlate with progression of diabetic neuropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Risk factors for renal failure: the WHO Mulinational Study of Vascular Disease in Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Cholesterol: a renal risk factor in diabetic nephropathy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Serum lipids and the progression of nephropathy in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Vascular risk factors and diabetic neuropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Energy metabolism and cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Peroxisome proliferator-activated receptor-alpha is required for the neurotrophic effect of oleic acid in neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Cortical expression of peroxisome proliferator-activated receptor-alpha after human brain contusion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Peroxisome Proliferator-activated Receptor α Activation Modulates Cellular Redox Status, Represses Nuclear Factor-κB Signaling, and Reduces Inflammatory Cytokine Production in Aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Activation and signaling by the AMP-activated protein kinase in endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetylcholine by altering the cyclooxygenase pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Peroxisome proliferator-activated receptor alpha interacts with high affinity and is conformationally responsive to endogenous ligands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Long-term n-3 FA deficiency modifies peroxisome proliferator-activated receptor beta mRNA abundance in rat ocular tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Cholesterol and cholesterol plus DHA diet-induced gene expression and fatty acid changes in mouse eye and brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Identification of functions of peroxisome proliferator-activated receptor alpha in proximal tubules.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Adipose differentiation-related protein and regulators of lipid homeostasis identified by gene expression profiling in the murine db/db diabetic kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Effect of gemfibrozil on serum levels of prostacyclin and precursor fatty acids in hyperlipidemic patients with Type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Physiological regulation of prostaglandins in the kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Fenofibrate increases creatininemia by increasing metabolic production of creatinine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Mechanisms of homocysteine-induced glomerular injury and sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

The treatment of hyperhomocysteinemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Serum homocysteine increases after therapy with fenofibrate or bezafibrate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Role of redox reactions in the vascular phenotype of hyperhomocysteinemic animals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARalpha-mediated effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Homocysteine-mediated PPARalpha,gamma DNA methylation and its potential pathogenic mechanism in monocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Peroxisome-proliferator-activated receptors and cancers: complex stories

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Fibrates and microvascular complications in diabetes--insight from the FIELD study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Fibrates, glitazones, and peroxisome proliferator-activated receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.89

Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20567246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20567246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Homocysteine-mediated thrombosis and angiostasis in vascular pathobiology

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20567246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRENDO.2010.89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20567246%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20567246%20AND%20SRC:MED&resulttype=core&format=json